The purpose of this study was to predict the stability of imipenem in a mixed infusion. The hydrolysis of imipenem in aqueous solution was found to be accelerated by pH, and by increasing concentrations of sodium bisulfite (SBS) and l-cysteine. Equations were derived for the degradation rate constants (k obs ) of pH, SBS and l-cysteine and fractional rate constants were estimated by nonlinear least-squares method (quasi-Newton method using the solver in Microsoft Excel) at 25°C. The activation energy (Ea) and frequency factor (A) were calculated using the Arrhenius equation. The pH of the mixed infusion was estimated using the pH characteristic (PHC) curve. From these results, an equation was derived giving the residual ratio (%) of imipenem at any time after mixing an infusion containing SBS and/or l-cysteine at any temperature and at pH 4.0-10.0. A high correlation was shown to exist between the estimated and determined residual ratios (%).
Imipenem-cilastatin sodium is a broad-spectrum intravenous antimicrobial product. Imipenem is a beta-lactam antibiotic, a N-formimidoyl derivative of thienamycin, which is usually administered in a mixture with cilastatin to prevent the renal degradation of imipenem. [1] [2] [3] [4] Cilastatin is a competitive inhibitor of the renal hydrolytic enzyme, dehydropeptidase I; it has no intrinsic antimicrobial activity, but retards the renal metabolism of imipenem. Imipenem has a broad antimicrobial activity against Gram-negative, Gram-positive and anaerobic pathogens, 1) which allows it to be used as a monotherapy, e.g., in the management of febrile neutropenia. 1, 2, [4] [5] [6] [7] [8] Sodium bisulfite (SBS), used as a stabilizer in injectable preparations, is known to degrade various drugs including thiamine, 9) epinephrine, 10) gabexate mesilate, 11) nafamostat mesilate, 12) urokinase, 13) morphine 14) and fluorouracil. 15) However, there are no reports of detailed kinetic studies on the degradation of imipenem in the presence of SBS.
Prediction of the stability of a drug in an intravenous admixture (mixed infusion) is important to permit accurate and safe drug administration. Generally, the stability of a drug in a mixed infusion can be predicted from the pH profile and Arrhenius equation of the degradation rate constants, if the temperature and pH of the test solution are known. Although imipenem is generally administered as an infusion in saline, in some cases it may be mixed with other substances, such as amino acids. 16) The method for pH prediction of mixed infusions was investigated in order to evaluate the compatibility of the components of the mixed infusion. Employing the pH characteristic curve (PHC curve; a kind of pH titration curve), 17) a method for pH estimation has been reported by Hirouchi et al. 18) based on computer simulations. However, the theoretical equations described by Hirouchi et al. were derived from model preparations for injection and did not take into account the influence of dilution with titrant. The PHC curve of a mixed infusion could not therefore be fitted to the equations of Hirouchi et al., but must be derived from observed values, a painstaking and time-consuming exercise. In the present study, a simple, theoretical, pH estimation method for mixed infusions was derived, using a fitted PHC curve and curve simulation by a computer (using Microsoft Excel).
In addition, we examined the degradation of imipenem due to catalytic hydrolysis by SBS and l-cysteine. From the results, we derived an equation to predict the residual ratio (%) of imipenem at any time after mixing, on the basis of the simulated pH of the mixed infusion using the PHC curve, SBS and l-cysteine concentrations, and the temperature.
Experimental
Materials Imipenem was supplied by Wako Pure Chemical Industries, Ltd., Osaka, Japan. SBS, cysteine and other reagents were special grade commercial products. As buffer solutions, 0.05 m acetate buffer (pH 4.0-5.0), 0.05 m phosphate buffer (pH 6.0-7.0) and 0.05 m carbonate buffer (pH 8.0-10.0) were adjusted to an ionic strength of 0.15 with sodium chloride. Imipenem plus cilastatin sodium 0.5 g for injection (Tienam ® for Intravenous Drip Infusion 0.5 g, Merck Sharp & Dohme Co., Ltd., Tokyo, Japan), AMINOLEBAN ® Injection, Fructlact Injection, and BFLUID ® Injection (Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan) and AMIGRAND ® (Terumo Co., Ltd., Tokyo, Japan) were used as injectable preparations.
Determination of Imipenem Imipenem concentration was measured by high-performance liquid chromatography (HPLC). Imipenem concentrations were determined 0, 1, 2, 3 and 4 h after mixing with SBS or l-cysteine. Each degradation rate constant (k obs ) was calculated from the slope of the relationship between the log residual ratio of imipenem (%) and time after mixing.
Equipment A Shimadzu LC-10AT VP high-performance liquid chromatograph, a Shimadzu SPD-10A VP UV-VIS detector, and a Shimadzu C-R7A plus chromatopack were used.
Measurement Conditions Column, CAPCELL PAK C 18 HPLC packed column type MG 5 µm (4.6 mm i.d.×150 mm); flow rate 2.2 mL/min; column oven set at 50°C; injection volume 10 µL; detection wavelength 250 nm. The mobile phase was 0.004 m sodium 3-[N-morpholino] propanesulfonic acid (MOPS Na) buffer with 1.0 g 1-hexanesulfonic acid sodium salt, plus 0.05 g disodium dihydrogen ethylendiamine tetraacetate dihydrate added to each litre. The mobile phase was adjusted to pH 7.0 with 0.1 m sodium hydroxide.
Estimation of the pH of the Mixed Infusion Observed values from pH titration were used to plot the PHC curve of the mixed infusion. Based on the general equation for PHC curves, the PHC curve of each preparation was fitted from the observed values, from which the pH of the mixed infusion could be estimated.
pH Titration Various commercial injections were diluted to 500 mL with distilled water and titrated against 0.5 m hydrochloric acid and sodium hydroxide. Similarly, 500 mL aliquots of various commercial infusions were titrated against 0.5 m hydrochloric acid and sodium hydroxide.
Fitting the PHC Curve of the Injection Preparation Injectable drugs are generally classified as weak acids, weak bases or salts. Taking a preparation of weak acid, with a total concentration of C a1 , the ionization of the weak acid may be represented as: HA→ H + +A − , where HA is the non-ionized acid, A − is the ionized acid and H + is hydrogen ion. Applying the law of mass action, material balance and charge balance to the equilibrium of this weak acid, the general equation of the PHC curve for the preparation can be expressed as in Eq. 1. Similarly, taking a preparation containing two kinds of weak acids of which the total concentrations are C a1 and C a2 , the general equation for the preparation can be expressed as in Eq. 2. If a preparation contains n kinds of weak acids, the general equation of the PHC curve for the preparation can be expressed as in Eq. 3. 
In order to improve solubility, preparations of weak bases often contain a strong acid as an excipient. The preparation of the weak base can therefore be assumed to be a preparation of a conjugated weak acid. Accordingly, the general equation of the PHC curve for the preparation of the weak base can be expressed as in Eq. 1, and the PHC curve of the preparation of n kinds of weak bases can be represented as in Eq. 3.
The general equation of the PHC curve for injectable preparations can therefore, for practical purposes, be represented as Eqs. 1, 2 or 3. The influence of dilution with titrants can be corrected by Eqs. 4-6.
where C a1 , C a2 , C a3 ,…, C an are the concentrations of weak acids 1, 2, 3 ,…, n in the sample solution, and K 1 , K 2, K 3 ,…, K n are the dissociation constants of the weak acids 1, 2, 3 ,…, n, respectively, C is the concentration of the strong acid (represented as a positive value) or the base (negative value) present as an excipient in the sample solution, and C t is the concentration of HCl (represented as a positive value) or NaOH (negative value), added as the titrant to the sample solution.
C′ an is the initial concentration of the weak acid and that of the strong acid (positive value) or base (negative value) in the sample solution, respectively. C′ t is the concentration of HCl or NaOH added to the sample solution as the titrant. V 0 is the initial volume of the titration sample (500 mL) and V t is the volume of the titrant added to the sample. [H + ] is the hydrogen ion concentration, and K w is the ion product of water.
For practical purposes, [H + ] and K w at 25°C were regarded as 10 −pH obs and 1.0×10 −14 , respectively. The parameters of the general equations for the PHC curve (i.e. concentrations and pKs of weak acids and concentrations of strong acid or base) were fitted with some of the observed values. The parameters of the PHC curve were then obtained by solving the simultaneous equation Eq. 2. Next, the parameters other than pK were fitted by the nonlinear least-squares method (simplex method). The PHC curves simulated by these parameters and the observed titration values were drawn graphically. If the PHC curve only partially fitted, the parameters of the PHC curve were modified by the simultaneous equation Eq. 1 and the simplex methods.
Simulation of the PHC Curve of Mixed Infusions
The effect of dilution was an important factor when the parameters of the PHC curve were fitted to the titration data. Nevertheless, once these parameters had been obtained, the PHC curves of the preparations could be treated simply according to Eqs. 1, 2, or 3, without Eqs. 4-6. Therefore, assuming the general equations of the PHC curves for an injection, an infusion, a mixed infusion consisting of these preparations and water, to be Eqs. 7, 8, 9 and 10, respectively, the relationship Eq. 9=Eq. 7+Eq. 8−Eq. 10 held at a constant ion concentration. Each of the terms except C tA , C tB , C tw and C tM could then be eliminated from Eqs. 7-10 at a constant hydrogen ion concentration, to obtain Eq. 11. Since each PHC curve represents the relation between the pH and the volume of the titrants (i.e. C tn ), the PHC curves of mixed infusions could be simulated by applying Eq. 11 at all pHs. If n kinds of preparations were mixed, the PHC curve of the mixed infusion could be simulated from the PHC curves of n−1 kinds of preparations and another additive injection.
Revision of the PHC Curve for Increased Infusion Volume The influence of dilution with additive injections is not included in Eq. 11. If the infusion volume is increased with additive injections, the PHC curves of the mixed infusion must be corrected by Eq. 12. This equation was obtained following the same process as for Eq. 11. tC t tw
where r is the concentration ratio (initial infusion volume (500 mL)/increased infusion volume with additives), C tC is the corrected concentration of HCl or NaOH (added as the titrant) in the mixed infusion at a constant pH, C t is the concentration of HCl or NaOH in a 500-mL aliquot of the mixed infusion at the same pH, and C tw is the concentration of HCl or NaOH in a 500-mL aliquot of distilled water at the same pH. At C t and C tw , the influence of dilution with additive injections was omitted.
Simulation of the PHC Curve of a Mixed Infusion
According to Eqs. 11 and 12, the PHC curve of the mixed infusion can be simulated from the PHC curves of each constituent preparation.
Estimated pH of a Mixed Infusion The pHs of the injections (diluted to 500 mL with distilled water) or infusions are represented by the pHs at the origin of the PHC curve of the preparations. The estimated pH of the mixed infusion was thus obtained as the pH at the origin of the simulated PHC curve.
Kinetic Procedures The stability of the imipenem solution (500 µg/mL) buffered at pH 4.0-10.0 in the presence of SBS (0, 0.1, 0.5, 1.0 mm) or l-cysteine (0, 0.25, 0.5, 1.0, 2.0 mg/ mL) was examined at 4°C, 25°C and 40°C. The stability of Tienam ® for Intravenous Drip Infusion 0.5 g in 500 mL of AMINOLEBAN ® Injection, 500 mL of Fructlact Injection, 500 mL of BFLUID ® Injection and 500 mL of AMIGRAND ® was examined at 4°C, 25°C, 40°C. Fig. 1 , where the rate constants are expressed on a logarithmic scale. It was concluded that specific hydrogen ion-catalyzed degradation occurred at pH 4.0-7.0, water-catalyzed degradation occurred at pH 7.0, and hydroxide ion-catalyzed degradation at pH 8.0-10.0.
Results and Discussion
As the data plot in Fig. 1 seemed to display specific acidbase catalysis kinetics, Eq. 13 was used as the model kinetic equation for the effect of pH on k 0 .
where k H + and k OH − are the second-order rate constants for the hydrogen-ion-catalyzed degradation and the hydroxide-ioncatalyzed degradation reaction, respectively, and k H2O is the first-order rate constant for the spontaneous water-catalyzed degradation reaction. At 25°C, the residual imipenem concentration determined by HPLC and [H + ], [OH − ] calculated from pH were assigned to Eq. 13. The fractional rate constants, k H2O , k OH − and k H + were estimated by the nonlinear least-squares method (quasi-Newton method using the solver in Microsoft Excel) and determined to be: k H2O 
The influence of temperature was also investigated. The Arrhenius equation (Eq. 14) shows the relationship between the degradation rate constant and the absolute temperature.
where k obs is the degradation rate constant, Ea is the activation energy, R is the gas constant (1.987 cal mol −1 ), T is absolute temperature (K), and A is the frequency factor. As shown in Degradation Rate of Imipenem in the Presence of SBS SBS, present as a stabilizer in injectable preparations, is known to degrade imipenem. 19) However, the mechanism by which the SBS concentration affects this degradation has not yet been elucidated. Therefore, kinetic experiments were performed, and the residual imipenem concentration measured Initial concentration of imipenem 500 µg/mL. ◇ pH 4.0, * pH 5.0, ◆ pH 6.0, × pH 7.0, ▲ pH 8.0, ○ pH 9.0, ■ pH 10.0 by HPLC. The degradation of imipenem, at an initial concentration of 500 µg/mL, by SBS at various concentrations was evaluated at 25°C and pH 4.0-10.0. The degradation rate constant of imipenem in the presence of SBS (k obs ) was measured at 25°C. A linear relationship was observed between time and log residual ratio (%) at pH 6.0 ( Fig. 3) , indicating that the degradation of imipenem followed pseudo-first-order kinetics. This was also the case at other pHs. The apparent first-order rate constants were obtained from the slopes of the semi-log plots. The slope of the line increased with increasing SBS concentration.
The rate constant for the catalytic hydrolysis of imipenem by SBS (k SBS ) is obtained from Eq. 15. obs 2.303 log 100
where k obs is the pseudo-first-order reaction rate constant, t is time after mixing, and r is the residual ratio (%). Typical plots for SBS concentration versus degradation rate constants of imipenem (pH 6.0, 25°C) yielded a straight line as shown in Fig. 4 . The fractional rate constants, k HSO3 − and k SO3 2− were estimated by nonlinear least-squares method (quasi-Newton method using solver in Microsoft Excel), and values of k HSO3 − (8.69 m −1 h −1 ) and k SO3 2− (35.37 m −1 h −1 ) were obtained. These results show that the accelerating effect of sulfite ions on the hydrolysis of imipenem was four times greater than that of bisulfate ions at pH 4.0-10.0 and 25°C.
The influence of temperature on the degradation of imipenem by SBS was also investigated. As shown in Fig. 5 , Arrhenius plots revealed good linearity between SBS concentrations of 0, 0.1, 0.5 and 1.0 mm at pH 6.0, and the values obtained for the activation energy (Ea) of imipenem, 11.94 kcal/mol, 12.24 kcal/mol, 11.40 kcal/mol, and 7.55 kcal/mol, respectively.
Degradation Rate of Imipenem in the Presence of l-Cysteine l-Cysteine is often added to infusions for purposes of nutrition. It may be present as the free amino acid or as N-acetylcysteine (NAC) which can be degraded by hydrolysis in the body. l-Cysteine is known to degrade carbapenem antibiotics, but the effect of the l-cysteine concentration on the rate of degradation has not been elucidated. Kinetic experiments were therefore carried out, with the residual imipenem concentrations measured by HPLC. The degradation of imipenem at an initial concentration of 500 µg/mL by various concentrations of l-cysteine or NAC was evaluated at 25°C and pH 4.0, 6.0, 8.0. The degradation rate constant of imipenem in the presence of l-cysteine (k cys ) was measured at 25°C. Typical plots for l-cysteine concentration versus degradation rate constants of imipenem yielded a straight line as shown in Fig. 6 . NAC concentrations were converted to l-cysteine concentrations. NAC itself appeared to have little effect on the degradation rate constants of imipenem. The degradation rate of imipenem was directly proportional to the total concentration of l-cysteine ([cys] total ). Based on the dissociation constant of l-cysteine at 25°C, k cys1 =1.20×10 −2 (pK cys1 =1.92), k cys2 =4.68×10 −9 (pK cys1 =8.33) and k cys3 =1.66×10 −11 (pK cys3 =10.78), 21) 
The fractional rate constants, k HSO3 − and k SO3 2− were estimated by the nonlinear least-squares method (quasi-Newton method using the solver in Microsoft Excel) to obtain the following values: k COO − · NH3 + SH (93.47 m −1 h −1 ), k COO − · NH3 + S − (27547.36 m −1 h −1 ) and k COO − · NH2･SH + (17.74 m −1 h −1 ). The value of k COOH · NH3 + · SH was much smaller than the other fractional rate constants, so k COOH · NH3 + · SH was omitted from the calculations, as it seems to have little effect on the degradation rate constants of imipenem.
The influence of temperature on the degradation of imipenem by l-cysteine was also investigated. As shown in Fig. 7 , Arrhenius plots revealed good linearity at l-cysteine concentrations of 0, 0.25, 0.5, 1.0 and 2.0 mg/mL at pH 6.0. The values obtained for the activation energy (Ea) of imipenem were 8.81 kcal/mol (0.25 mg/mL), 10.14 kcal/mol (0.5 mg/ mL), 11.15 kcal/mol (1.0 mg/mL) and 13.75 kcal/mol (2.0 mg/ mL), while the value obtained for the activation energy (Ea) of imipenem was 11.94 kcal/mol in the absence of l-cysteine (0 mg/mL). There were little difference between the values of Ea in presence of l-cysteine and the value of Ea in absence of l-cysteine. The dose-dependent effect of l-cystene on Ea of imipenem in this reaction is suggested to be small. The log k obs of imipenem showed temperature-dependently increase in any concentration of l-cysteine. Moreover, the log k obs of imipenem showed l-cysteine concentration-dependently increase in any temperature. From these results, the degradation of imipenem is suggested to be increased temperature-dependently and lcysteine concentration dependently. Initial concentration of imipenem 500 µg/mL. ◇ l-cysteine 0 mg/mL, ○ l-cysteine 0.25 mg/mL, △ l-cysteine 0.5 mg/mL, □ l-cysteine 1.0 mg/mL, × l-cysteine 2.0 mg/mL. pH Estimation Method for a Mixed Infusion After mixing Tienam ® for Intravenous Drip Infusion 0.5 g with AMINOLEBAN ® Injection, Fructlact Injection, BFLUID ® Injection or AMIGRAND ® , the pH was estimated at 25°C using the PHC curve. Figure 8 shows the correlation between the estimated and determined pH values in the mixed infusion (y=0.9928x, r 2 =0.9944). The pH of each mixed infusion could be estimated correctly using the PHC curve.
Stability Prediction of Imipenem in Practical Mixed Infusions From the above results, the degradation rate constant of imipenem after mixture with an infusion contained SBS and l-cysteine at pH 4.0-10.0, can be represented by Eq. 25. ) exp( / )
where Ea 1 is the activation energy in the presence of the acid-base catalytic effect, Ea 2 is the activation energy in the presence of SBS, Ea 3 is the activation energy in the presence of l-cysteine; k obs at any temperature (T 2 ) can be calculated if 298 K (25°C) is assigned to T 1 and the derived concentrations and constants at 298 K (25°C) and activation energy values The imipenem product used in clinical field, Tienam ® for Intravenous Drip Infusion 0.5 g is the drug combination of imipenem and cilastatin sodium. While, SBS is reported to increase the hydrolysis of β-lactam ring and ester. There is no functional group undergone hydrolysis increased by SBS in cilastatin sodium. l-Cysteine is also known to increase the hydrolysis of β-lactam ring, 22) however, there is no functional group undergone hydrolysis increased by l-cysteine in cilastatin sodium. Consequently, we examined the degradation of only imipenem due to catalytic hydrolysis by pH, SBS and l-cysteine.
The correlation between the estimated and determined residual ratio (%) of imipenem in Tienam ® for Intravenous Drip Infusion 0.5 g at 0, 1, 2, 3 and 4 h after mixing with AMINOLEBAN ® Injection, Fructlact Injection, BFLUID ® Injection or AMIGRAND ® at 4, 25 and 40°C (y=1.022x−3.055, r 2 =0.983) is shown in Fig. 9 . The high correlation coefficient q 2 , (0.979) shows high correlation between the estimated in this study and the determined residual ratio (%) of imipenem in the drug combination used in clinical field.
These results confirm that an equation predicting the stability of imipenem, at any time and any temperature, after mixing with an infusion containing SBS and l-cysteine at pH 4.0-10.0 has been derived in this study.
Conclusion
The key factors influencing the stability of imipenem in a The volume of each infusion is 500 mL. y=0.9928x, r 2 =0.9944. Fig. 9 . Correlation between Estimated and Observed Residual Ratio (%) after Mixing Tienam ® for Intravenous Drip Infusion 0.5 g with AMINOLEBAN ® Injection, Fructlact Injection, BFLUID ® Injection or AMIGRAND ® at 4°C, 25°C and 40°C
The volume of each infusion is 500 mL. y=1.022x−3.055, r 2 =0.983. ○ AMINOLEBAN ® Injection at 4°C, □ Fructlact Injection at 4°C, ◇ BFLUID ® Injection at 4°C, △ AMIGRAND ® at 4°C. • AMINOLEBAN ® Injection at 25°C, ■ Fructlact Injection at 25°C, ◆ BFLUID ® Injection at 25°C, ▲ AMIGRAND ® at 25°C. • AMINOLEBAN ® Injection at 40°C, ■ Fructlact Injection at 40°C, ◆ BFLUID ® Injection at 40°C, ▲ AMIGRAND ® at 40°C. mixed infusion were found to be pH, SBS concentration, and l-cysteine concentration. Equations describing the degradation rate constants (k obs ) for pH, SBS and l-cysteine have been derived, and the activation energy (Ea) and frequency factor (A) calculated using the Arrhenius equation. The pH of the mixed infusion could be estimated using the PHC curve. Finally, an equation has been derived giving the residual ratio (%) of imipenem at any time after mixing any infusion at any temperature at pH 4.0-10.0. A high correlation was shown between the estimated and the determined values for residual ratio (%). The equation derived in this study will enable us to predict the concentration of imipenem in mixed infusions and will therefore improve the correct use of this drug.
